InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,949.20
(
1.06%
)
Post# of 252428
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rogerm

Send PM Follow Ignore
Followers 2
Posts 112
Boards Moderated 0
Alias Born 08/04/2005

rogerm

Re: poorgradstudent post# 210490

Friday, 04/07/2017 5:31:36 AM

Friday, April 07, 2017 5:31:36 AM

Post# of 252428
Incyte has an agreement with LLY that prevents it from using an oral tab for Alopecia areata or for Vitiligo so it is testing a 1.5% cream for both with some success. Jakafi's pricetag is >$100,000 per yr. Lilly probably doesn't want to see a cheaper oral derma version on the market. Link shows impressive results for oral ruxolitinib in small AA trial. http://insight.jci.org/articles/view/89790/figure/2
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up